Genmab Confident It Has Edge Over Roche In Bispecific Battle
Epcoritamab Tipped To Lead Rival CD20xCD3 Drugs
Genmab only recently launched its commercial division with Tivdak, but is now preparing for a possible 2023 launch of epcoritamab. • Source: Genmab 
